CHI Saint Joseph Health Cancer Care Centers, sponsored by Catholic Health Initiatives, participates in the National Cancer Institute’s (NCI) community oncology research program – a national NCI-supported network that brings cancer prevention and treatment clinical trials and cancer care delivery research (CCDR) to people in their communities.
As a patient, you or your loved one have direct access to multiple clinical trials that could offer alternatives to standard treatments and more choice for care, while advancing medical research.
Taking part in a study is your choice, and you’re free to leave at any time. Your oncologist will talk with you about benefits, risks and what to expect.
Clinical trials are held at our dedicated cancer centers throughout Central Kentucky, so you don’t have to travel far to access these potentially breakthrough treatments.
Breast Cancer Studies
We offer ongoing clinical trials for a variety of cancers, with a special focus on prevention, detection and treatment of breast cancer, including metastatic. Past breast cancer trials have shown the benefit of hormone therapies and certain drugs that are now standard parts of treatment. As new therapies are developed, they can open doors to other medicines and procedures that may be even more effective.
Explore Open Cancer Clinical Trials
See all of our current clinical trials below. For more information, including how to enroll, call 859.313.2960.
- HER2+ metastatic breast cancer
- Triple negative metastatic breast cancer
- Adjuvant therapy for triple negative breast cancer
- High risk HR+ positive stage II-III disease
- HR+ disease that has progressed after aromatase inhibitor
- Weight loss study for breast cancer patients diagnosed within the last year
- Second line treatment of squamous NSCLC
- First line therapy for resected NSCLC
- Adjuvant treatment of stage III colon cancer with DNA mismatch repair deficiency
- First line therapy for metastatic colon cancer with DNA mismatch repair deficiency
- Study looking at the financial impact of newly diagnosed stage IV colon cancer
- Stage III-IV BRAFv600e mutated melanoma
- Melanoma that has advanced after taking an Anti-PD1/L agent
- Newly diagnosed metastatic sarcoma in patients under the age of 50
- Stage IV or unresectable sarcoma
- First line treatment for newly diagnosed Multiple Myeloma
- Registry trial for newly diagnosed or newly recurrent myeloma
- Study looking at fertility after a cancer diagnosis in females of childbearing potential with newly diagnosed cancer